MK 3854
Alternative Names: MK-3854Latest Information Update: 17 Nov 2022
At a glance
- Originator Merck & Co
- Developer Bill & Melinda Gates Medical Research Institute; Merck & Co
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 18 Oct 2022 Merck and Bill & Melinda Gates Medical Research Institute (Gates MRI) enters into licensing agreement for the further development and distribution of MK 3854
- 18 Oct 2022 Preclinical trials in Tuberculosis in USA (unspecified route)
- 18 Oct 2022 Pharmacodynamics data from preclinical studies in Tuberculosis released by Merck